Biologics & Biosimilars

Biosimilars the Generic form of organic is the new popular expression in pharmaceutical industry. Biosimilars are exceptionally like authorized reference item not withstanding minor contrasts in clinically idle parts; additionally there are no clinically significant contrasts between the organic and the reference item as far as wellbeing, virtue, and strength. This track incorporates: Licensing of Biosimilars, Biomarkers direction, Patent issues, BLA petitioning for Biosimilars, Regulatory prospects of BRIC nations, a worldview of customary generics to Biosimilars, Biologics& Bio waiver endorsement for Biosimilars and different parts of Biosimilar endorsements.

  • Bio-analytics for Biosimilars
  • Extrapolation and Interchangeability
  • Legal Considerations for Biosimilars
  • Biosimilar Uptake and Market Considerations
  • Challenges and regulatory approach for biosimilars
  • Future of next generation biosimilars

Related Conference of Biologics & Biosimilars

February 28-March 01, 2019 ANA Crowne Plaza |

Global Pharmaceutical and Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
July 26-27, 2019

13th Asian Biologics and Biosimilars Congress

Mercure Albert Park | Melbourne, Australia

Biologics & Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in